For HER2-positive gastric cancer, trastuzumab has shown significant efficacy when combined with chemotherapy in the ToGA trial (NCT01041404), becoming a classic example of HER2-targeted therapy [3, 283]. This evidence concerns the gene ERBB2 and gastric cancer.